Current options and approaches for blood management in orthopaedic surgery

Journal of Bone and Joint Surgery

Volumn 80, Issue 5, 1998, Pages 750-762

  Michael Keating, E ^a  

^a CENTER FOR HIP AND KNEE SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; BLOOD SUBSTITUTE; COLLAGEN; DESMOPRESSIN; FIBRIN GLUE; FLUOROCARBON; HEMOGLOBIN; OXYGEN; PERFLUORODECALIN; PERFLUOROOCTYL BROMIDE; RECOMBINANT ERYTHROPOIETIN; THROMBIN; TRANEXAMIC ACID;

BLEEDING; BLOOD DONOR; BLOOD TRANSFUSION; CLINICAL TRIAL; DRUG EFFICACY; HEMOSTASIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SURGICAL TECHNIQUE; TOPICAL DRUG ADMINISTRATION;

EID: 0031808581     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Amberson, W. R.; Jcnnings, J. J.; and Rhode, C. M.: Clinical experience with hemoglobin-saline solutions. J. Appl. Physiol, 1: 469-489, 1949.
2. American Association of Blood Ianks: Standards for Blood Banks and Transfusion Services, edited by P. V. Holland and P. H. Schmidt. Ed. 12. Arlington, Virginia, American Association of Blood Banks, 1987.
3. Arnestad, J. P.; Bcngtsson, A.; Bengtson, J. P.; Tjlman, M.; Rcdl, H.; and Schlag, G.: Formation of cytokines by retransfusion of shed whole blood. British J. Anaesth., 72:422-425, 1994.
4. AuBuchon, J. P.: Cost-effectiveness of preoperative autologous blood donation for orthopedic and cardiac surgeries. Am. J. Med., 101: 38S-42S, 1996.
5. Audet, A.-M., and Goodnough, L.T.: Practice strategies for elective red blood cell transfusion. Ann. Intern. Med., 116:403-406, 1992.
6. Ayers, D. C.; Murray, D. G.; and Ducrr, D. M.: Blood salvage after total hip arthroplasty. J. Bone and Join! Surg., 77-A: 1347-1351, Sept. 1995.
7. Bcnoni, G., and Fredin, H.: Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty. A prospective, randomised, double-blind study of 86 patients. J. Bone and Joint Surg., 78-B(3): 434-440, 1996.
8. Benoni, G.; Lcthagcn, S.; and Frcdin, II.: The effect of tranexamic acid on local and plasma fibrinolysis during total knee arthroplasty. Thromb. Res., 85:195-206, 1997.
9. Benoni, G.; Carlsson, A.; Petcrsson, C.; and Frcdin, H.: Does tranexamic acid reduce blood loss in knee arthroplasty? Am. J. Knee Surg., 8:88-92, 1995.
10. Boris, P.; Mcrmillod, B.; Levy, G.; Laubriat, M.; Soulier-Laupcr, M.; Tullen, E.; Hugli, A.; and Mieschcr, P. A.: Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. A prospective study. Vox Sang., 65:212-218, 1993.
11. Biro, G. P.: Perfluorocarbon-based red blood cell substitutes. Transfus. Med. Rev., 1:84-95, 1993.
12. Biro, G. P., and Biais, P.: Perfluorocarbon blood substitutes. Crit;. Rev. OncoL-Hematol, 6:311-374, 1987.
13. Blumberg, N., and Heal, J. M.: Immunomodulatiori byttood transfusion: an evolving scientific and clinical challenge. Am. J. Med., 101: 299-308, 1996.
14. Bunn, H. F.; Esliam, VV. T.; and Bull, R. W.: The renal handling of hemoglobin. I. Glomerular filtration. J. Exper. Med., 129:909-923, 1969.
15. Bursten, S.; Weeks, R.; West, J.; Le, T.; Wilson, T.; Porubek, D.; Bianco, J. A.; Singer, J. W.; and Rice, G. C.: Potential role for phosphatidic acid in mediating the inflammatory responses to TNF alpha and IL-1 beta. Circ. Shock, 44:14-29, 1994.
16. Canadian Orthopedic Pcriopcralive Erythropoietin Study Group: Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet, 341:1227-1232, 1993.
17. Carson, J. L., and Wctt, L. R.: Is a hemoglobin of 10 g/dL required for surgery? Med. din. North America, 77:335-347, 1993.
18. Cazenavc, J. P.; Sondag, D.; Genctct, B.; Laxcnairc, M. C.; Dupont, E.; Poisson, D.; and Dabout, D.: Recombinant human erythropoietin in nonanaemic patients scheduled for orthopaedic or cardiovascular surgery, to facilitate perisurgical autologous blood donation [abstract]. British J. Anaestli., 74 (Supplement 1): 64,1995.
19. Cazenavc, J. P.; Irrmann, C.; Waller, C.; Sondag, D.; Baudoux, E.; Genetet, B.; Laxcnaire, M. C.; Dupont, E.; Sundal, E.; Obrist, R.; and Stocker, H.: Epoetin alfa facilitates presurgical autologous blood donation in non-anaemic patients scheduled for orthopaedic or cardiovascular surgery. European J. Anaestliesiol., 14:432-442, 1997.
20. Chcn, R. H.; Frazier, O. II.; and Cooley, D. A.: Antifibrinolytic therapy in cardiac surgery. Texas Heart Inst. J., 22:211-215, 1995.
21. Cohcn, J. A., and Brecher, M. E.: Preoperative autologous blood donation: benefit or detriment? A mathematical analysis. Transfusion, 35:640-644, 1995.
22. Council on Scientific Affairs, American Medical Association: Autologous blood transfusions. J. Am. Med. Assn., 256:2378-2380, 1986.
23. Gumming, P. D.; Wallace, E. L.; Schorr, J. B.; and Dodd, R. Y.: Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody-negative. New England J. Med., 321:941-946, 1989.
24. D'Ambra, M. N., and Kaplan, D. K.: Alternatives to allogeneic blood use in surgery: acute normovolemic hemodilution and preoperative autologous donation. Am. J. Surg., 170 (Supplement 6A): 49S-52S, 1995.
25. Davidson, B. L.; Elliolt, C. G.; Lcnsing, A. W.; and The RD Heparin Arthroplasty Group: Low accuracy of color Doppler ultrasound in the detection of proximal leg vein thrombosis in asymptomatic high-risk patients. Ann. Intern. Med., 117:735-738, 1992.
26. de andradc, J. R.; Jove, M.; Landon, G.; Frei, D.; Guilfoyle, M.; and Young, D. C.: Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients. Am. J. Orthop., 25:533-542, 1996.
27. Devine, P.; Postoway, N.; Hoffstadler, L.; Surgenor, D. M.; Linden, J. V.; Hines, D.; Chcmoff, A.; Ciavarclla, D.; and Bove, J. R.: Blood donation and transfusion practices: the 1990 American Association of Blood Banks Institutional Membership Questionnaire. Transfusion, 32:683-687, 1992.
28. Dietz, N. M.; Joyner, M. J.; and Warner, M. A.: Blood substitutes: fluids, drugs, or miracle solutions? Anesth. and Analg., 82:390-405, 1996.
29. Dodd, R. Y.: The risk of transfusion-transmitted infection [editorial]. New England J. Med., 327:419-421, 1992.
30. Domen, R. E.: Preoperative autologous blood donation: clinical, economic, and ethical issues. Cleveland Clin. J. Med., 63:295-300, 1996.
31. Donahue, J. G.; Munoz, A.; Ness, P. M.; Brown, D. E., Jr.; Yawn, D. H.; McAllister, H. A., Jr.; Reitz, B. A.; and Nelson, K. E.: The declining risk of post-transfusion hepatitis C virus infection. New England}. Med., 327:369-373, 1992.
32. Eschbach, J. W.; Egrie, J. C.; Downing, M. R.; Browne, J. K.; and Adamson, J. W.: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. New England J. Med., 316:73-78, 1987.
33. Faithful), N. S.; Kcipcrt, P. E.; Rhoadcs, G. E.; Bradley, J. D.; and Trouwborst, A.: Development and validation of a computer model for evaluation of efficacy of perfluorochemical emulsions. Artif. Cells, Blood Substitutes, and Immobil. Biotechnol., 22: A96, 1994.
34. Faris, P. M.; Ritter, M. A.; Abels, R. I.; and The American Erythropoietin Study Group: The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. J. Bone and Joint Surg., 78-A: 62-72, Jan. 1996.
35. Faris, P. M.; Kilter, M. A.; Kcating, E. M.; and Valeri, C. R.: Unwashed filtered shed blood collected after knee and hip arthroplasties. A source of autologous red blood cells.J. Bone and Joint Surg., 73-A: 1169-1178, Sept. 1991.
36. Fasulo, F.; Giori, A.; Fissi, S.; Bozzctti, F.; Doci, R.; and Gcnnari, L.: Cavitron Ultrasonic Surgical Aspirator (CUSA) in liver resection. Internat. Surg., 77:64-66,1992.
37. Fernandez, M. C.; Gottlich, M.; and Menitove, J. E.: Blood transfusion and postoperative infection in orthopedic patients. Transfusion, 32:318-322, 1992.
38. Fratantoni, J. C.: Blood substitutes: problems and prospects. In Limiting Donor Exposure in Hemolherapy, pp. 61-73. Edited by J. P. AuBuchon and L. A. Issitt. Bethesda, Maryland, American Association of Blood Banks, 1994.
39. Gannon, D. M.; Lombardi, A. V., Jr.; Mallory, T. H.; Vaughn, B. K.; Finney, C. R.; and Niemcryk, S.: An evaluation of the efficacy of postoperative blood salvage after total joint arthroplasty. A prospective randomized trial. J. Arthroplasty, 6:109-114, 1991.
40. Goldbcrg, M. A.; McCutchen, J. W.; Jove, M.; Di Cesare, P.; Friedman, R. J.; Poss, R.; Guilfoyle, M.; Frei, D.; and Young, D.: A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am. J. Orthop., 25: 544-552, 1996.
41. Goodnough, L. T., and Brillenham, G. M.: Limitations of the erythropoietic response to serial phlebotomy: implications for autologous blood donor programs.J. Lab. and Clin. Med., 115:28-35, 1990.
42. Goodnough, L. T., and Despolis, G. J.: Establishing practice guidelines for surgical blood management. Am. J. Surg., 170 (Supplement 6A): 16S-20S, 1995.
43. Goodnough, L. T.; Shafron, D.; and Marcus, R. E.: The impact of preoperative autologous blood donation on orthopaedic surgical practice. Vox Sang., 59:65-69, 1990.
44. Goodnough, L. T.; Soegiarso, R. W.; and Gcha, A. S.: Blood lost and blood transfused in coronary artery bypass graft operation as implications for blood transfusion and blood conservation strategies. Siirg., Gynec. and Obstet., 177:345-351, 1993.
45. Goodnough, L. T.; Vcrbruuge, D.; and Marcus, R. E.: The relationship between hematocrit, blood lost, and blood transfused in total knee replacement. Implications for postoperative blood salvage and reinfusion. Am. J. Knee Stirg., 8:83-87, 1995.
46. Goodnough, L. T.; Price, T. H.; Rudnick, S.; and Soegiarso, R. W.: Preoperative red cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy. Transfusion, 32:441-445, 1992.
47. Goodnough, L. T.; Vizmeg, K.; Sobecks, R.; Schwarz, A.; and Soegiarso, W.: Prevalence and classification of anemia in elective orthopedic surgery patients: implications for blood conservation programs. Vox Sang., 63:90-95, 1992.
48. Goodnough, L. T.; Price, T. H.; Friedman, K. D.; Johnston, M.; Ciavarella, D.; Khan, N.; Sacher, R.; Vogler, W. R.; Wisse), M.; and Abels, R. L: A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy. Transfusion, 34:66-71, 1994.
49. Goodnough, L. T.; Rudnick, S.; Price, T. H.; Ballas, S. K.; Collins, M. L.; Crowley, J. P.; Kosmin, M.; Kruskall, M. S.; Lenes, B. A.; Menitove, J. E.; Silberstcin, L. E.; Smith, K. J.; Wallas, C. H.; Abels, R.; and Von Tress, M.: Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy.New England]. Med., 321:1163-1168, 1989.
50. Graf, IL; Watzinger, U.; Ludvik, B.; Wagner, A.; Hocker, P.; and Zweymuller, K. K.: Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. British Med.J., 300:1627-1628, 1990.
51. Man, C. D., and Shin, D. E.: Postoperative blood salvage and reinfusion after total joint arthroplasty. J. Artliroplasty, 12:511-516, 1997.
52. Hayes, A.; Murphy, D. B.; and McCarroll, M.: The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery. J. Clin. Anestli., 8:357-360, 1996.
53. Hiippala, S. T.; Strid, L. J.; Wcnnerstrand, M. L; Arvcla, J. V.; Nicincla, H. M.; Mantyla, S. K.; Kuisma, R. P.; and Ylincn, J. E.:Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. Anestli. and Analg., 84:839-844, 1997.
54. Hochreiter, J.; Nielsche, D.; Oswald, J.; Jakubck, H.; Michlmayr, G.; and Hohenwallncr, W.: [Preoperative autologous blood collection under erythropoietin stimulation. Preliminary results in patient selection, erythropoietin dosage and administration.] Zeitschr. Orthop. Crenzgeb., 130:519-523, 1992.
55. Hong, F.; Shasfri, K. A.; Loguc, G. L.; and Spaulding, M. B.: Complement activation by artificial blood substitute Fluosol: in vitro and in vivo studies. Transfusion, 31:642-647, 1991.
56. Howes, J. P.; Sharma, V.; and Cohen, A. T.: Tranexamic acid reduces blood loss after knee arthroplasty. J. Bone and Joint Siirg., 78-B(6): 995-996, 1996.
57. HubmajT, R. D., and Rodartc, J. R.: Acute and long-term effects of Fluosol-DA 20% on respiratory system mechanics and diffusion capacity in dogs.J. Crit. Care, 3:232-239, 1988.
58. Hull, R.; Raskob, G.; Pinco, G.; Rosenbloom, D.; Evans, W.; Mallory, T.; Anquist, K.; Smith, F.; Hughes, G.; Green, D.; Elliott, C. G.; Panju, A.; and Brant, R.: A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. New England J. Med., 329:1370-1376, 1993.
59. Huo, M. IL; Paly, W. L.; and Kcggi, K. J.: Effect of preoperative autologous blood donation and intraoperative and postoperative blood recovery on homologous blood transfusion requirement in cementless total hip replacement operation. J. Am. Coll. Surgeons, 180: 561-567,1995.
60. Imperiale, T. F., and Speroff, T.: A meta-analysis of methods to prevent venous thromboembolism following total hip replacement J.Am. Med. Assn., 271:1780-1785,1994; erratum, 273:288, 1995.
61. Isaacs, C.; Paltiel, O.; Blake, G.; Bcaudet, M.; Conochie, L.; and Lcclcrc, J.: Age-associated risks of prophylactic anticoagulation in the setting of hip fracture. Am. J. Med., 96:487-491, 1994.
62. Jansscns, M.; Joris, J.; and David, J. L.: High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. Aneslhesiology, 80:23-29, 1994.
63. Karnezis, T. A.; Stulbcrg, S. D.; Wixson, R. L.; and Reilly, P.: The hemostatic effects of desmopressin on patients who had total joint arthroplasty. A double-blind randomized trial. J. Bone and Joint Siirg., 76- A: 1545-1550, Oct. 1994.
64. Keipert, P. E.: Use of Oxygent, a perfluorochemical-based oxygen carrier, as an alternative to intraoperative blood transfusion. Artif. Cells, Blood Substitutes, and Immobil. Biolechnol., 23:381-394, 1995.
65. Keipert, P. E.; Faithful!, N. S.; Bradley, J. D.; Hazard, D. Y.; Hogan, J.; Lcviscfti, M. S.; and Peters, R.: Oxygen delivery augmentation by lowdose perfluorochemical emulsion during profound normovolemic hemodilution. In Oxygen Transport to Tissue XV, pp. 197-204. Edited by P. Vaupel, R. Zander, and D. F. Bruley. New York, Plenum Press, 1994.
66. Kickler, T. S., and Spirak, J. L.: Effect of repeated whole blood donations on serum immunoreactive erythropoietin levels in autologous donors. J. Am. Med. Assn., 260:65-67, 1988.
67. Klein, H. G.: Allogeneic transfusion risks in the surgical patient. Am. J. Surg., 170 (Supplement 6A): 21S-26S, 1995.
68. Kraay, M. J.; Goldberg, V. M.; and Herbener, T. E.: Vascular ultrasonography for deep venous thrombosis after total knee arthroplasty. Clin. Orthop., 286:18-26, 1993.
69. Kram, H. B.; Nathan, R. C.; Stafford, F. J.; Fleming, A. W.; and Shoemaker, W. C.: Fibrin glue achieves hemostasis in patients with coagulation disorders. Arch. Surg., 124:385-387, 1989.
70. Lamm, D. L.; Craw ford, E. D.; Blumcnstcin, B.; Crissman, J.; deVcrc White, R.; Wolf, M.; Lowe, B.; Sarosdy, M.; Schcllhammcr, P.; Sagalowsky, A.; Smith, J.; Grossman, H. B.; Flanigan, R.; Moon, X; Brendlcr, C.; and Coltman, C.: SWOG 8795: a randomized comparison of bacillus Calmette-Guérin and mitomycin C prophylaxis in stage TA and Tl transitional cell carcinoma of the bladder [abstract]. J.Urol., 149:282A, 1993.
71. Landymorc, R. W.; Murphy, J. T.; Lummis, H.; and Carter, C.: The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations. European J. CardioThoracic Surg., 11:798-800,1997.
72. Law, J. K., and Wledel, J. D.: Autotransfusion in revision total hip arthroplasties using uncemented protheses. Clin. Orthop., 245: 145-149,1989.
73. Lefevre, P.; Tryba, M.; Fournel, J. J.; Gagenzel, C.; Poisson, D.; Dabout, D.; and Manclli, J. C.: Recombinant human erythropoietin in nonanaemic patients scheduled for elective surgery to facilitate presurgical autologous blood donation combined with normovolaemic haemodilution [abstract]. British J. Anaesth., 74 (Supplement 1): 64, 1995.
74. Llau, J. V.; Hoyas, L.; Higucras, J.; Ezpeleta, J.; and Garcia-Polit, J.: [Aprotinin reduces intraoperative bleeding during spinal arthrodesis interventions] [letter]. Rev. Espanola Anestesiol. Reanim., 43:118, 1996.
75. Marks, R. M.; Vaccaro, A. R.; Baldcrslon, R. A.; Hozack, W. J.; Booth, R. E., Jr.; and Rothman, R. H.: Postoperative blood salvage in total knee arthroplasty using the Solcotrans autotransfusion system. J. Arthroplasty, 10:433-437, 1995.
76. Mercuriali, F.; Gualtieri, G.; Biffi, E.; Inghillcri, G.; Colotti, M. T.; Vinci, A.; and Scalamogna, R.: Randomized, double-blind, placebocontrolled dose-finding study with recombinant human erythropoietin to facilitate autologous blood donation in low haematocrit patients undergoing total hip replacement [abstract]. British J. Anaesth., 74 (Supplement 1): 63, 1995.
77. Mercuriali, F.; Zanclla, A.; Barosi, G.; Inghillcri, G.; Biffi, E.; Vinci, A.; and Colotti, M. T.: Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion, 33:55-60, 1993.
78. Mercurial!, E; Gualtieri, G.; Sinigaglia, L.; Inghillcri, G.; Biffi, E.; Vinci, A.; Colotti, M. T.; Barosi, G.; and Lambcrtengh Dclilicrs, G.: Use of recombinant human erythropoietin to assist autologous blood donation by anemic rheumatoid arthritis patients undergoing major orthopedic surgery. Transfusion, 34:501-506,1994.
79. Messmer, K.; Krcimeier, U.; and Intaglictta, M.: Present state of intentional hemodilution. European Surg. Res., 18:254-263, 1986.
80. Mezrow, C. K.; Bergstein, I.; and Tarttcr, P. I.: Postoperative infections following autologous and homologous blood transfusions. Transfusion, 32:27-30, 1992.
81. Miller, E.; Paull, D. E.; Morrissey, K.; Cortese, A.; and Nowak, E.: Scalpel versus electrocautery in modified radical mastectomy. Am. Surg., 54:284-286, 1988.
82. Mohr, D. N.; Silvcrstcin, M. D.; Murtaugh, P. A.; and Harrison, J. M.: Prophylactic agents for venous thrombosis in elective hip surgery. Meta-analysis of studies using venographic assessment. Arch. Intern. Med., 153:2221-2228, 1993.
83. Mott, L. S., and Jones, M. J.: Autologous blood donation in a small general acute-care hospital. J. Nat. Med. Assn., 87:549-552, 1995.
84. Murkin, J. M.; Shannon, N. A.; Bourne, R. B.; Rorabcck, C. H.; Cruickshank, M.; and Wyile, G.: Aprotinin decreases blood loss in patients undergoing revision or bilateral total hip arthroplasty. Anesth. andAnalg., 80:343-348, 1995.
85. Murphy, P.; Heal, J. M.; and Blumberg, N.: Infection or suspected infection after hip replacement surgery with autologous or homologous blood transfusions. Transfusion, 31:212-217, 1991.
86. National Institutes of Health Consensus Conference: Perioperative red blood cell transfusion. J. Am. Med. Assn., 260:2700-2703, 1988.
87. Nelson, C. L., and Bowen, W. S.: Total hip arthroplasty in Jehovah's Witnesses without blood transfusion. J. Bone and Joint Surg., 68-A: 350-353, March 1986.
88. Nelson, C. L., and Fontenot, H. J.: Ten strategies to reduce blood loss in orthopedic surgery. Am. J. Surg., 170 (Supplement 6A): 64S-68S, 1995.
89. O'Bricn, B. J.; andcrson, D. R.; and Goeree, R.: Cost-effectiveness of enoxaparin versus warfarin. prophylaxis against deep-vein thrombosis after total hip replacement. Canadian Med. Assn. J., 150:1083-1090, 1994.
90. Oishi, C. S.; D'Lima, D. D.; Morris, B. A.; Hardtvick, M. E.; Berkowitz, S. D.; and Colwcll, C. W., Jr.: Hemodilution with other blood reinfusion techniques in total hip arthroplasty. Clin. Orthop., 339:132-139, 1997.
91. Parodi, J. C.; Criado, F. J.; Barone, H. D.; Schonholz, C.; and Queral, L. A.: Endoluminal aortic aneurysm repair using a balloonexpandable stent-graft device: a progress report. Ann. Vase. Surg., 8:523-529, 1994.
92. Pellegrini, V. D., Jr.; Langhans, M. J.; Tolterman, S.; Marder, V. J.; and Francis, C. W.: Embolie complications of calf thrombosis following total hip arthroplasty. J. Arthroplasty, 8:449-457, 1993.
93. Penta dc Peppo, A.; Pierri, M. D.; Scafuri, A.; DC Paulis, R.; Colantuono, G.; Caprara, E.; Toinai, E; and Chiariello, L.: Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs. Texas Heart Inst. J., 22: 231-236, 1995.
94. Price, T. H.; Goodnough, L. T.; Vogler, W.; Sachet, R.; Hellman, R.; Johnston, M.; Bolgiano, D.; Abels, R.; and EPO Autologous Study Group: Effect of recombinant human erythropoietin (epoetin alfa) administration on allogeneic blood use during orthopaedic surgery [abstract]. British J. Anaesth., 74 (Supplement 1): 64, 1995.
95. Riess, J. G.: Fluorocarbon-based in vivo oxygen transport and delivery systems. Vox Sang., 61:225-239, 1991.
96. Robergc, J. Q.: Search narrows for "blood substitutes." Biotech. Lab. hist., 6, 1996.
97. Rosenblatt, M. A.; Cantos, E. M., Jr.; and Mohandas, K.: Intraoperative hemodilution is more cost-effective than preoperative autologous donation for patients undergoing procedures associated with a low risk for transfusion. J. Clin. Anesth., 9:26-29, 1997.
98. Schott, U.; Sollen, C.; Axelsson, K.; Rugarn, P.; and Allvin, L: Desmopressin in acetate does not reduce blood loss during total hip replacement in patients receiving dexlran. Acta Anaesthesiol. Scandinavica, 39:592-598, 1995.
99. Schreiber, S.; Howaldt, S.; Sclmoor, M.; Nikolaus, S.; Bauditz, J.; Gasche, C.; Lochs, H.; and Raedlcr, A.: Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. New England J. Med., 334:619-623, 1996.
100. Schriemcr, P. A.; Longnecker, D. E.; and Mintz, P. D.: The possible inmmunosuppressive effects of perioperative blood transfusion in cancer patients. Anesthesiology, 68:422-428, 1988.
101. Scott, M. G.; Kucik, D. F.; Goodnough, L. T.; and Monk, T. G.: Blood substitutes: evolution and future applications. Clin. Client., 43: 1724-1731, 1997.
102. Sculco, T. P.: Blood management in orthopedic surgery. Am. J. Surg., 170 (Supplement 6A): 60S-63S, 1995.
103. Shah, D. M.; Chang, B. B.; Paly, P. S.; Kaufman, J. L.; Koslow, A. R.; and Leather, R. P.: Treatment of abdominal aortic aneurysm by exclusion and bypass: an analysis of outcome.J. Vase. Surg., 13:15-22, 1991.
104. Sharrock, N. E.; Minco, R.; Urquhart, B.; and Salrali, E. A.: The effect of two levels of hypotension on intraoperative blood loss during total hip arthroplasty performed under lumbar epidural anesthesia. Anesth. and Analg., 76:580-584, 1993.
105. Simpson, M. B.; Murphy, K. P.; Chambers, H. G.; and Buckncll, A. L.: The effect of postoperative wound drainage reinfusion in reducing the need for blood transfusions in elective total joint arthroplasty: a prospective, randomized trial. Orthopedics, 17:133-137, 1994.
106. Slagis, S. V.; Benjamin, J. B.; Volz, R. G.; and Giordano, G. F.: Postoperative blood salvage in total hip and knee arthroplasty. A randomised controlled trial.J. Bone and Joint Surg., 73-B(4): 591-594, 1991.
107. Spcncc, R. K.: Surgical red blood cell transfusion practice policies. Blood Management Practice Guidelines Conference. Am. J. Surg., 170 (Supplement 6A): 3S-15S, 1995.
108. Spence, R. K.; Carson, J. A.; Poses, R.; McCoy, S.; Pcllo, M.; Alexander, J.; Popovich, J.; Norcross, E.; and Camishion, R. C.: Elective surgery without transfusion: influence of preoperative hemoglobin level and blood loss on mortality. Am. J. Surg., 159:320-324, 1990.
109. Storring, P. L., and Gaines Das, R. E.: The international standard for recombinant DNA-derived erythropoietin: collaborative study for four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins. J. Endrocrinol., 134: 459-484, 1992.
110. Strang, T. I., and Whitaker, D. K.t Blood conservation strategies. Citrr. Opin. Anesthesiol, 7:53-58, 1994.
111. Surgcnor, D. M.; Wallace, E. L.; Hao, S. H.; and Chapman, R. H.: Collection and transfusion of blood in the United States, 1982-1988. New England]. Med., 322:1646-1651, 1990.
112. Tasaki, T.; Ohio, H.; Hashimoto, C.; Abe, R.; Saitoh, A.; and Kikuchi, S.: Recombinant human erythropoietin for autologous blood donation: effects on perioperative red-blood-cell and serum erythropoietin production. Lancet, 339:773-775, 1992.
113. Tcrblanche, J.; Krige, J. E.; and Bornman, P. C: Simplified hepatic resection with the use of prolonged vascular inflow occlusion. Arch. Surg., 126:298-301, 1991.
114. Theroux, M. C.; Corddry, D. H.; Tietz, A. E.; Miller, F.; Peoples, J. D.; and Kcttrick, R. G.: A study of desmopressin and blood loss during spinal fusion for neuromuscular scoliosis: a randomized, controlled, doubleblinded study. Anesthesiology, 87:260-267, 1997.
115. Toy, P. T.; Kaplan, E. B.; McVay, P. A.; Lee, S. J.; Strauss, R. G.; Stchling, L. C.; and The Preoperative Autologous Blood Donation Study Group: Blood loss and replacement in total hip arthroplasty: a multicenter study. Transfusion, 32:63-67, 1992.
116. Triulzi, D. J.; Vanek, K.; Ryan, D. H.; and Blumbcrg, N.: A clinical and immunologie study of blood transfusion and postoperative bacterial infection in spinal surgery. Transfusion, 32:517-524, 1992.
117. Tryba, M.: Epoetin alfa plus autologous blood donation in patients with a low hematocrit scheduled to undergo orthopedic surgery. Sem. Hematol, 33 (2 Supplement 2): 22-24, 1997.
118. Tryba, M.; Kindler, D.; and Schulte-Tamburen, A.: Preoperative use of recombinant human erythropoietin (epoetin alfa) in patients scheduled for orthopaedic surgery to facilitate autologous blood donation [abstract]. British J. Anaesth., 74 (Supplement 1): 63, 1995.
119. Utada, K.; Matayoshi, Y.; Sumi, C.; Itaya, M.; Miyanaki, H.; Ito, M.; Tamura, H.; and Mitsukuji, T.: [Aprotinin 2 million KIU reduces perioperative blood loss in patients undergoing primary total hip replacement]. Japanese J. Anesthesiol., 46:77-82, 1997.
120. Vanivakas, E. C., and Moore, S. B.: Blood transfusion and postoperative septic complications. Transfusion, 34:714-727, 1994.
121. Vamvakas, E. C., and Taswell, H. F.: Epidemiology of blood transfusion. Transfusion, 34:464-470, 1994.
122. Viele, M. K., and Weiskopf, R. B.: What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses. Transfusion, 34:396-401, 1994.
123. Wasman, J., and Goodnough, L. T.: Autologous blood donation for elective surgery. Effect on physician transfusion behavior. J.Am. Med. Assn., 258:3135-3137,1987.
124. West, J.: Respiratory Physiology -the Essentials. Ed. 3, p. 69. Baltimore, Williams and Wilkins, 1985.
125. Winearls, C. G.; Oliver, D. O.; Pippard, M. J.; Reid, C.; Downing, M. R.; and Cotes, P. M.: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet, 2:1175-1178, 1986.
126. Woolson, S. T., and Watt, J. M.: Use of autologous blood in total hip replacement. A comprehensive program. J. Bone and Joint Surg., 73-A: 76-80, Jan. 1991.
127. Wyman, A., and Rogers, K.: Randomized trial of laser scalpel for modified radical mastectomy. British J. Surg., 80:871-873, 1993.
128. Yusuf, S. W.; Baker, D. M.; Chuter, T. A.; Whilaker, S. C.; Wcnham, P. W.; and Hopkinson, B. R.: Transfemoral endoluminal repair of abdominal aortic aneurysm with bifurcated graft. Lancet, 344:650-651, 1994.
129. Zuckerman, A. J.: The new GB hepatitis viruses. Lancet, 345:1453-1454, 1995.